HVC
TCRT icon

Healthcare Value Capital’s Alaunos Therapeutics TCRT Stock Holding History

Healthcare Value Capital’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-667
Closed -$394K – 46
2013
Q3 		$394K Hold
667
– – 0.34% 45
2013
Q2 		$211K Buy
+667
New +$185K 0.15% 55

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Healthcare Value Capital's TCRT Position: Q4 2013 in Review

Healthcare Value Capital sold out of Alaunos Therapeutics (TCRT) in Q4 2013, closing a stake of 667 shares — an estimated $394K sold.

Healthcare Value Capital first reported a position in TCRT in Q2 2013 and held it in 2 quarters. The position peaked at $394K in Q3 2013. 78 funds tracked by Wall St. Rank hold TCRT as of Q4 2013.

  • Healthcare Value Capital reported no remaining Alaunos Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Healthcare Value Capital sold 667 Alaunos Therapeutics shares in Q4 2013, an estimated $394K.
  • Healthcare Value Capital first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 2 quarters.
  • Healthcare Value Capital's Alaunos Therapeutics position peaked at $394K in Q3 2013.
  • 78 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2013.

Based on Healthcare Value Capital's 13F filing for Q4 2013, filed 13 Feb 2014.